RETA (GLP-3) 15mg

What is RETA (GLP-3)?

RETA (GLP-3) is an investigational metabolic peptide being studied for activity across three important hormonal receptor pathways: GLP-1, GIP and glucagon.

This triple-receptor activity makes RETA (GLP-3) a particularly interesting area of metabolic research, allowing researchers to investigate several interconnected pathways involved in energy balance, glucose regulation, appetite signalling, metabolic function and body composition.

Unlike compounds that primarily investigate one metabolic signalling pathway, RETA (GLP-3) provides a research model involving three complementary receptor systems within a single molecule.

RETA (GLP-3) continues to be investigated in clinical and laboratory research, with researchers studying its mechanisms, metabolic effects and longer-term characteristics.

Why is RETA (GLP-3) interesting?

The three receptor pathways associated with RETA (GLP-3) each play important roles in metabolic biology.

GLP-1 signalling is associated with glucose-dependent insulin secretion, appetite signalling and gastrointestinal regulation. GIP signalling is involved in nutrient sensing and glucose-dependent insulin secretion and is being investigated for its broader effects on metabolic regulation. Glucagon receptor signalling plays an important role in hepatic metabolism, energy mobilisation and the body's response to changing energy demands.

The ability to investigate these three pathways together is what makes RETA (GLP-3) particularly interesting within modern metabolic research.

RETA (GLP-3) & GLP-1 Signalling

GLP-1 is a naturally occurring hormone released in response to food intake and plays an important role in glucose homeostasis.

• Glucose-dependent insulin secretion
• Appetite regulation
• Gastrointestinal activity
• Glucose metabolism
• Nutrient signalling
• Energy balance

RETA (GLP-3) allows researchers to investigate GLP-1 receptor activity alongside GIP and glucagon receptor signalling, creating an opportunity to study the interaction between these different metabolic pathways.

RETA (GLP-3) & GIP Signalling

GIP, or glucose-dependent insulinotropic polypeptide, is another naturally occurring incretin hormone involved in the body's response to nutrient intake.

GIP signalling is being investigated in relation to glucose metabolism, insulin secretion, nutrient sensing and broader metabolic processes. One area of interest is how GIP signalling interacts with GLP-1 signalling and whether these pathways can produce complementary metabolic effects when investigated together.

RETA (GLP-3) provides researchers with a model for exploring this interaction alongside glucagon receptor activity.

RETA (GLP-3) & Glucagon

Glucagon is an important hormone involved in maintaining energy availability and regulating hepatic metabolism.

• Energy mobilisation
• Hepatic glucose regulation
• Substrate utilisation
• Energy expenditure
• Metabolic adaptation

The addition of glucagon receptor activity distinguishes RETA (GLP-3) from research compounds that primarily focus on incretin signalling alone. Researchers are interested in understanding how glucagon signalling interacts with GLP-1 and GIP pathways to influence overall metabolic regulation.

RETA (GLP-3) & Metabolic Research

Metabolic research involves a complex network of hormones and signalling pathways that regulate how the body responds to food intake, energy availability and changing metabolic demands.

Current research has explored:

• Body-weight regulation
• Appetite signalling
• Glucose regulation
• Energy balance
• Metabolic health
• Body composition
• Insulin-related pathways
• Energy expenditure

Clinical research continues to investigate the compound across different populations and metabolic conditions, while its longer-term safety and characteristics remain areas of ongoing study.

RETA (GLP-3) & Appetite Research

Appetite is regulated by a complex network of hormonal and neurological signals. GLP-1 and GIP signalling are both involved in nutrient-related hormonal responses, while glucagon signalling contributes to broader energy regulation.

RETA (GLP-3) provides researchers with an opportunity to investigate how simultaneous activity across these three pathways may influence appetite-related signalling, food intake and energy balance.

RETA (GLP-3) & Energy Balance

Energy balance describes the relationship between energy intake and energy expenditure. Multiple hormonal pathways contribute to this process, including GLP-1, GIP and glucagon signalling.

Research in this area is helping scientists explore the relationship between nutrient intake, energy expenditure, fuel utilisation and metabolic signalling.

RETA (GLP-3) & Body Composition Research

Body composition research looks beyond total body weight to investigate changes in components such as fat mass, lean mass and overall metabolic parameters.

Researchers continue to investigate how triple-receptor activity may influence energy balance and body-composition-related measurements. Findings should be interpreted within the specific population, study design and conditions in which they were obtained.

RETA (GLP-3) & Glucose Research

Glucose regulation is one of the major areas of interest surrounding GLP-1 and GIP signalling. Both pathways are involved in glucose-dependent insulin secretion, while glucagon plays an important role in maintaining glucose availability and hepatic metabolism.

Studying these pathways simultaneously allows researchers to investigate the interaction between incretin signalling, insulin-related responses and glucagon activity.

What makes RETA (GLP-3) different?

• Triple-receptor activity: GLP-1, GIP and glucagon receptor pathways.
• Metabolic signalling: Interconnected pathways involved in metabolic regulation.
• Appetite research: Hormonal pathways involved in food intake and satiety.
• Energy-balance research: Energy intake, expenditure and fuel utilisation.
• Glucose research: Glucose-dependent insulin and glucagon signalling.
• Body-composition research: Metabolic and body-composition-related outcomes.
• Multi-pathway model: Three major metabolic signalling systems within one investigational molecule.

A New Direction in Metabolic Research

RETA (GLP-3) represents an interesting direction in metabolic peptide research because it brings together three major hormonal pathways within a single investigational molecule.

Rather than focusing exclusively on one receptor system, RETA (GLP-3) allows researchers to investigate the interaction between GLP-1, GIP and glucagon signalling.

Research continues to examine the compound's mechanisms, metabolic effects and longer-term characteristics.

Peptigen RETA (GLP-3) 15mg is supplied strictly for laboratory research purposes.

Research Areas at a Glance

GLP-1 Signalling • GIP Signalling • Glucagon Receptor • Metabolic Regulation • Appetite Research • Energy Balance • Glucose Research • Body Composition • Energy Expenditure

Product Details

• Product: RETA (GLP-3)
• Size: 15mg per vial
• BAC Water: Included
• Format: Lyophilised research compound
• Price: R950.00
• Intended use: Laboratory and scientific research only

Research Disclaimer

RETA (GLP-3) is an investigational research compound and is not currently approved by SAHPRA, the FDA, or other major regulatory authorities for therapeutic or consumer applications.

Peptigen products are provided exclusively for laboratory research. Information on this website is presented for general scientific and educational purposes and should not be considered medical advice, a treatment recommendation, or guidance for personal use.

Research involving RETA (GLP-3) continues to develop, and research findings should always be interpreted within the context of the specific study, population, research model and conditions under which they were obtained.

Peptigen does not provide dosing, administration or reconstitution guidance for research compounds. Purchasers are responsible for ensuring that research materials are handled within an appropriate research environment and in accordance with relevant laws, regulations, laboratory protocols and safety requirements.

Research use only.